CAR-T Therapy

Chimeric antigen receptor (CAR)-T therapy is a remarkable advancement in the fight against cancer. Landmark approvals of Kymriah and Yescarta in 2017 set the stage for rapid growth in the sector and just a few short years later, over 400 clinical trials are underway. As the industry continues to move at an unprecedented speed, we provide Solutions that help immune cell therapy developers and manufacturers stay ahead of the curve and lower their COGs. These solutions are specifically designed to address the unique challenges and goals of CAR-T R&D, process development and manufacturing.
 

CAR-T Therapy Research & Development

Learn more

CAR-T Therapy Process Development

Learn more

CAR-T Therapy Manufacturing

Learn more
Contact a CAR-T Therapy Consultant